Anthem Biosciences IPO 2025: GMP, Price Band, Lot Size, Dates & Full Investment Guide
Anthem Biosciences Limited, a leading innovation-driven Contract Research, Development, and Manufacturing Organization (CRDMO), is launching its ₹3,395 crore IPO. The public issue opens on July 14, 2025 and closes on July 16, 2025. The IPO has already generated buzz with a current Grey Market Premium (GMP) of ₹100, suggesting strong investor interest.
Anthem Biosciences IPO Key Details
| IPO Open Date | July 14, 2025 |
|---|---|
| IPO Close Date | July 16, 2025 |
| Listing Date | July 21, 2025 (Tentative) |
| Price Band | ₹540 – ₹570 |
| Lot Size | 26 shares |
| Minimum Investment | ₹14,820 |
| Offer Size | ₹3,395 crore (OFS) |
| Face Value | ₹2 |
| Employee Discount | ₹50 |
Anthem Biosciences Limited, a leading innovation-driven Contract Research, Development, and Manufacturing Organization (CRDMO), is launching its ₹3,395 crore IPO. The public issue opens on July 14, 2025 and closes on July 16, 2025. The IPO has already generated buzz with a current Grey Market Premium (GMP) of ₹100, suggesting strong investor interest. The IPO GMP is approximately 18%.
Grey Market Premium (GMP) Trends
| Date | GMP (₹) | GMP (%) |
|---|---|---|
| July 11, 2025 | ₹108 | 18% |
| July 12, 2025 | ₹155 | 27.19% |
| July 13, 2025 | - | - |
About Anthem Biosciences Ltd.
Founded in 2006 and headquartered in Bengaluru, Anthem Biosciences Ltd. is a fast-growing CRDMO that caters to the global life sciences industry. The company provides end-to-end drug development solutions, specializing in small molecules, peptides, biosimilars, fermentation-based APIs, enzymes, and probiotics.
- 550+ global clients from the US, Europe, and Japan
- 196 ongoing projects (as of September 2024)
- 7 overseas patents, 1 Indian patent, 24 global filings
- 600+ scientists, including PhDs, biologists, and chemists
Financial Performance (₹ in Crores)
| FY | Revenue | EBITDA | PAT | Total Assets | Net Worth |
|---|---|---|---|---|---|
| FY23 | 1,134 | 446 | 385 | 2,014 | 1,741 |
| FY24 | 1,483 | 520 | 367 | 2,398 | 1,925 |
| FY25 | 1,930 | 684 | 451 | 2,808 | 2,410 |
Valuation & Financial Ratios
- EPS: ₹8.07
- P/E Ratio: 70.62x
- ROE: 20.82%
- ROCE: 26.88%
- EBITDA Margin: 36.81%
- P/B Ratio: 13.23
- Debt to Equity: 0.05 (low debt)
Lot Size & Investment Limits
| Category | Lots | Shares | Investment (₹) |
|---|---|---|---|
| Retail Min | 1 | 26 | ₹14,820 |
| Retail Max | 13 | 338 | ₹1,92,660 |
| sNII Min | 14 | 364 | ₹2,07,480 |
| bNII Min | 68 | 1,768 | ₹10,07,760 |
Promoter Holding
- Pre-IPO: 76.87%
- Post-IPO: 74.68%
- Promoters: Ajay Bhardwaj, Ganesh Sambasivam, K. Ravindra Chandrappa, Ishaan Bhardwaj
About Anthem Biosciences Ltd.
Anthem Biosciences Limited, founded in 2006 and headquartered in Bengaluru, is a cutting-edge Contract Research, Development, and Manufacturing Organization (CRDMO) serving the global pharmaceutical and biotech sectors. The company specializes in offering fully integrated services across the drug discovery-to-commercialization lifecycle for both New Chemical Entities (NCEs) and New Biological Entities (NBEs).
Anthem stands out for its innovation-driven approach and scalable infrastructure, making it one of India’s fastest-growing players in the CRDMO space. Its client base spans over 550 companies across more than 44 countries, including the U.S., Europe, and Japan—ranging from early-stage biotech startups to multinational pharma giants.
The company's key focus areas include fermentation-based Active Pharmaceutical Ingredients (APIs), peptides, enzymes, biosimilars, probiotics, and vitamin analogues. As of September 30, 2024, Anthem is working on 196 ongoing projects, which include discovery, early phase, late phase, and commercial manufacturing assignments.
The company has a robust intellectual property pipeline, with 1 Indian patent, 7 overseas patents, and 24 global patent applications currently under review. Its team includes more than 600 scientists and technical experts such as medicinal chemists, biologists, microbiologists, and chemical engineers, making it a knowledge-intensive organization with high scientific capability.
With its consistent financial growth, global reach, scientific depth, and minimal debt, Anthem Biosciences is strategically positioned to capitalize on the increasing global outsourcing demand in the life sciences sector.
Anchor Investor Details
- Anchor Allocation: ₹1,016.02 Cr
- Shares Allotted: 1.78 crore shares on July 11, 2025
- Lock-in Period: 50% till August 16, 2025, Rest till October 15, 2025
Anthem Biosciences has strong fundamentals, global presence, high GMP, and a low debt profile. With positive investor sentiment and long-term potential in the CRDMO space, this IPO can be considered by both growth-focused and listing-gain investors.
Anthem Biosciences IPO GMP, Anthem IPO price band, Anthem IPO lot size, Anthem Biosciences financials, Anthem Biosciences listing date, Anthem Biosciences IPO subscription status
Disclaimer: This article is for informational purposes only and not investment advice. Please consult your financial advisor before investing.
Join WhatsApp Group
